We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00434512
First Posted: February 13, 2007
Last Update Posted: November 1, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
  Purpose
GSK has constructed a new HIV immunogen comprised of conserved parts of the HIV virus (gag, pol and nef). The principal objectives of this study are to evaluate the reactogenicity and safety of this candidate vaccine with or without a GSK proprietary adjuvant system at three different doses and to evaluate the CD4+ T-cell response in terms of proportion of responders to the antigens two weeks after the second vaccination.

Condition Intervention Phase
AIDS Biological: HIV vaccine 732461 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Dose-ranging Study to Compare the Safety and Immunogenicity of a Candidate Human Deficiency Virus (HIV) Vaccine 732461, Adjuvanted or Not, Administered According to a 0, 1 Month Schedule to Healthy Adult HIV Seronegative Volunteers.

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Number of subjects with any and Grade 3 solicited local symptoms [ Time Frame: During the 7-day (Days 0-6) follow-up period after each vaccination and overall ]
    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

  • Number of subjects with any, Grade 3 and related solicited general symptoms [ Time Frame: During the 7-day (Days 0-6) follow-up period after each vaccination and overall ]
    Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

  • Number of subjects with any, Grade 3 and related unsolicited adverse events (AEs) [ Time Frame: During the 30-day (Days 0-29) follow-up period after each vaccination and overall ]
    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

  • Number of subjects with serious adverse events (SAEs) [ Time Frame: During the whole study period (From Month 0 to Month 12) ]
    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

  • Number of subjects with abnormal haematological and biochemical levels [ Time Frame: At Month 0 ]
    The frequency distribution of values below, within and above normal ranges, as well as changes from baseline, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells [RBC] count, haemoglobin, haematocrit, white blood cell [WBC] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase [ALT] and aspartate aminotransferase [AST].

  • Number of subjects with abnormal haematological and biochemical levels [ Time Frame: At Month 1 ]
    The frequency distribution of values below, within and above normal ranges, as well as changes from baseline, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells [RBC] count, haemoglobin, haematocrit, white blood cell [WBC] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase [ALT] and aspartate aminotransferase [AST].

  • Number of subjects with abnormal haematological and biochemical levels [ Time Frame: At Day 44 ]
    The frequency distribution of values below, within and above normal ranges, as well as changes from baseline, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells [RBC] count, haemoglobin, haematocrit, white blood cell [WBC] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase [ALT] and aspartate aminotransferase [AST].

  • Number of subjects with abnormal haematological and biochemical levels [ Time Frame: At Month 2 ]
    The frequency distribution of values below, within and above normal ranges, as well as changes from baseline, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells [RBC] count, haemoglobin, haematocrit, white blood cell [RBC] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase [ALT] and aspartate aminotransferase [AST].

  • Number of subjects with abnormal haematological and biochemical levels [ Time Frame: At Month 6 ]
    The frequency distribution of values below, within and above normal ranges, as well as changes from baseline, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells [RBC] count, haemoglobin, haematocrit, white blood cell [WBC] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase [ALT] and aspartate aminotransferase [AST].

  • Number of subjects with abnormal haematological and biochemical levels [ Time Frame: At Month 7 ]
    The frequency distribution of values below, within and above normal ranges, as well as changes from baseline, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells [RBC] count, haemoglobin, haematocrit, white blood cell [WBC] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase [ALT] and aspartate aminotransferase [AST].

  • Number of subjects with abnormal haematological and biochemical levels [ Time Frame: At Month 12 ]
    The frequency distribution of values below, within and above normal ranges, as well as changes from baseline, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells [RBC] count, haemoglobin, haematocrit, white blood cell [WBC] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase [ALT] and aspartate aminotransferase [AST].

  • Number of subjects with a response in terms of cluster of differentiation 4 (CD4+) T-cells expressing at least two cytokines including IL-2 equal or above the cut-off to at least 1, 2, 3 antigens and to all 4 antigens [ Time Frame: At Day 44 ]
    Antigen-specific CD4+ T-cells can express cluster of differentiation 40-ligand (CD40-L) and produce the cytokines Interleukin 2 (IL-2) and/or Tumor Necrosis Factor alpha (TNF-α) and/or Interferon-gamma (IFN-γ). The frequency of antigen specific CD4+ T-cells was calculated as the difference between the frequency of CD4+ T-cells producing at least 2 cytokines (among IFN-g, IL-2, TNF-a and/or CD40L), upon in vitro stimulation with the peptide pools derived from the antigen minus the frequency of CD4+ T-cells producing at least 2 cytokines upon in vitro stimulation in medium only.


Secondary Outcome Measures:
  • Frequency of p17, p24, Nef and RT-specific CD4+ T-cells expressing IL-2 and at least another marker [ Time Frame: At Months 0, 2, 6, 12 and at Day 44 ]
    Antigen-specific CD4+ T-cells can express CD40 ligand (CD40-L) and produce the cytokines Interleukin 2 (IL-2) and/or Tumor Necrosis Factor alpha (TNF-α) and/or Interferon-gamma (IFN-γ). Frequency of CD4+ T-cells expressing markers in response to the F4co fusion protein (all antigens) was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (p17, p24, Nef, RT). Results are presented as determined by Intracellular Cytokine Staining (ICS).

  • Frequency of p17, p24, Nef and RT-specific CD4+ T-cells expressing at least 2 immune markers [ Time Frame: At Months 0, 2, 6, 12 and at Day 44 ]
    Antigen-specific CD4+ T-cells can express CD40 ligand (CD40-L) and produce the cytokines Interleukin 2 (IL-2) and/or Tumor Necrosis Factor alpha (TNF-α) and/or Interferon-gamma (IFN-γ). Frequency of CD4+ T-cells expressing markers in response to the F4co fusion protein (all antigens) was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (p17, p24, Nef, RT). Results are presented as determined by Intracellular Cytokine Staining (ICS).

  • Antibody titers against p17, p24, Nef, RT and F4co antigens [ Time Frame: At Months 0, 2, 6, 12 and at Day 44 ]
    Anti-p17, -p24, -Nef, -RT and -F4co antibody titers were measured by Enzyme Linked Immunosorbent Assay (ELISA) and presented as geometric mean titers (GMTs).


Enrollment: 180
Actual Study Start Date: February 20, 2007
Study Completion Date: June 13, 2008
Primary Completion Date: June 13, 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SB732461 adjuvanted_LD Group
Healthy adult HIV seronegative subjects aged 18 to 40 years, received two doses of the adjuvanted low-antigen dose [LD] SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
Biological: HIV vaccine 732461
Experimental: SB732461 adjuvanted_MD Group
Healthy adult HIV seronegative subjects aged 18 to 40 years, received two doses of the adjuvanted middle-antigen dose [MD] SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
Biological: HIV vaccine 732461
Experimental: SB732461 adjuvanted_HD Group
Healthy adult HIV seronegative subjects aged 18 to 40 years, received two doses of the adjuvanted high-antigen dose [HD] SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
Biological: HIV vaccine 732461
Experimental: SB732461 non-adjuvanted_LD Group
Healthy adult HIV seronegative subjects aged 18 to 40 years, received two doses of the non-adjuvanted low-antigen dose [LD] SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
Biological: HIV vaccine 732461
Experimental: SB732461 non-adjuvanted_MD Group
Healthy adult HIV seronegative subjects aged 18 to 40 years, received two doses of the non-adjuvanted middle-antigen dose [MD] SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
Biological: HIV vaccine 732461
Experimental: SB732461 non-adjuvanted_HD Group
Healthy adult HIV seronegative subjects aged 18 to 40 years, received two doses of the non-adjuvanted high-antigen dose [HD] SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
Biological: HIV vaccine 732461

Detailed Description:
This is a single center, observer-blind, randomized, dose-escalating, staggered study with 6 groups: 3 groups of 50 subjects receiving the adjuvanted candidate vaccine, at 3 different doses and 3 groups of 10 subjects receiving the non-adjuvanted candidate vaccine in water for injection, at 3 different doses. The vaccination schedule will be 0-1 month. Blood samples will be collected at 8 visits. The duration of the study will be approximately 14 months for each subject. Rationale for Protocol Posting Amendment: The third vaccination will be cancelled and the visit at Month 7 will be postponed to Month 9. The Protocol Posting has also been updated in order to comply with the FDA Amendment Act, Sep 2007.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • A male or female between and including 18-40 years at the time of first vaccination.
  • Written informed consent obtained from the subject prior to any study procedure.
  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
  • Good general health without significant medical history, physical examination findings, or clinically significant abnormal laboratory results.
  • If the subject is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.
  • Negative for antibodies against HIV-1, HIV-2 and negative for HIV p24 antigen within 56 days (8 weeks) prior to enrolment. Subjects must be willing to accept HIV test results. Individuals who elect not to receive test results will not be enrolled.
  • Negative for anti-HBc Ab, HBsAg and anti-HCV Ab.

Exclusion Criteria:

  • Women who are pregnant or breast-feeding.
  • Subjects with a history of, or current, alcohol or substance abuse.
  • The subject is at high risk of acquiring HIV according to the behavioural risk assessment questionnaire.
  • Morbid obesity
  • Previous inclusion in a HIV vaccines trial.
  • Receipt of live attenuated vaccines within 30 days of enrolment.
  • Receipt of medically indicated subunit or killed vaccines or allergy treatment with antigen injections within 14 days of study vaccine administration.
  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Prior receipt of HIV-1 vaccines or placebo in a previous HIV vaccine trial.
  • Receipt of blood products 120 days prior to HIV screening.
  • Receipt of immunoglobulin 120 days prior to HIV screening.
  • History of serious adverse reactions including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema and abdominal pain to vaccines.
  • History of serious allergic reaction to any substance requiring hospitalization or emergency medical care.
  • History of immunodeficiency or autoimmune disease.
  • History of malignancy (unless there has been surgical excision followed by a sufficient observation period, of at least 5 years, to give a reasonable assurance of sustained cure and which, in the estimate of the investigator, is not likely to recur during the study period).
  • Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccination.
  • History of type I or type II diabetes mellitus including cases controlled with diet alone. A subject with past gestational diabetes is eligible.
  • Thyroid disease including history of thyroidectomy and diagnoses requiring medication. A subject not requiring thyroid medicine within the past 12 months is eligible.
  • Acute disease at the time of enrolment.
  • Asthma requiring daily steroid or long acting β agonist prevention.
  • Unstable asthma.
  • Food- or wine-induced asthma.
  • Known sensitivity to sulfites or aspirin.
  • Bleeding disorder that was diagnosed by a physician. A subject who states that he or she has easy bruising or bleeding, but does not carry a formal diagnosis and has intramuscular (IM) injections and blood draws without any adverse experience is eligible.
  • History of any serious neurologic disorder or seizure
  • History of major congenital defect
  • History of chronic fatigue syndrome or fibromyalgia
  • Splenectomy
  • Hypertension. A subject with hypertension is eligible if he or she is controlled on medication and the documented blood pressure is less than 150/100.
  • Any medical, psychiatric or social condition, or occupational or other responsibility that, in the judgement of the investigator, would interfere with or serve as a contradiction to adherence to the study protocol or ability to give informed consent.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00434512


Locations
Belgium
GSK Investigational Site
Gent, Belgium, 9000
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline